Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.24% | 39.49% | 42.25% | 28.33% | 27.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.24% | 39.49% | 42.25% | 28.33% | 27.78% |
| Cost of Revenue | 41.48% | 36.17% | 13.80% | 41.51% | 29.56% |
| Gross Profit | 41.12% | 41.44% | 68.05% | 22.39% | 26.91% |
| SG&A Expenses | 22.29% | 33.81% | 15.19% | 5.11% | 24.46% |
| Depreciation & Amortization | 3,400.00% | 1,540.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.46% | 37.70% | 14.50% | 19.81% | 27.05% |
| Operating Income | 50.02% | 46.15% | 684.81% | 56.69% | 29.49% |
| Income Before Tax | -2.78% | 1.69% | 1,578.91% | 47.23% | 53.34% |
| Income Tax Expenses | -6.20% | -65.77% | 619.12% | 44.03% | 36.03% |
| Earnings from Continuing Operations | -1.43% | 34.33% | 2,405.06% | 49.08% | 61.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.43% | 34.33% | 2,405.06% | 49.08% | 61.40% |
| EBIT | 50.02% | 46.15% | 684.81% | 56.69% | 29.49% |
| EBITDA | 63.16% | 55.40% | 517.57% | 54.31% | 29.12% |
| EPS Basic | -3.56% | 31.66% | 2,386.36% | 49.22% | 64.16% |
| Normalized Basic EPS | 36.07% | 31.11% | 367.85% | 51.19% | 27.74% |
| EPS Diluted | -3.92% | 31.13% | 2,311.62% | 47.67% | 64.52% |
| Normalized Diluted EPS | 35.52% | 29.65% | 367.52% | 49.87% | 27.81% |
| Average Basic Shares Outstanding | 2.21% | 2.02% | 0.80% | -0.10% | -1.68% |
| Average Diluted Shares Outstanding | 2.63% | 3.17% | 0.88% | 0.78% | -1.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |